Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XENE Stock Forecast 2025-2026
$44.53
Current Price
$3.48B
Market Cap
Buy 20
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XENE Price Targets
+46.0%
To High Target of $65.00
+23.5%
To Median Target of $55.00
-1.2%
To Low Target of $44.00
XENE Price Momentum
+3.8%
1 Week Change
+16.4%
1 Month Change
+5.9%
1 Year Change
+13.6%
Year-to-Date Change
-4.4%
From 52W High of $46.60
+66.5%
From 52W Low of $26.74
📊 TOP ANALYST CALLS
Did XENE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xenon is one of their latest high-conviction picks.
Latest XENE Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, XENE has a bullish consensus with a median price target of $55.00 (ranging from $44.00 to $65.00). The overall analyst rating is N/A (N/A/10). Currently trading at $44.53, the median forecast implies a 23.5% upside. This outlook is supported by 20 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 46.0% upside. Conversely, the most conservative target is provided by Benjamin Burnett at Wells Fargo, suggesting a 1.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XENE Analyst Ratings
20
Buy
0
Hold
0
Sell
XENE Price Target Range
Low
$44.00
Average
$55.00
High
$65.00
Current: $44.53
Latest XENE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XENE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 18, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $60.00 |
| Nov 4, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $58.00 |
| Nov 4, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $44.00 |
| Nov 4, 2025 | Needham | Serge Belanger | Buy | Reiterates | $55.00 |
| Oct 7, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $55.00 |
| Sep 3, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Assumes | $48.00 |
| Sep 2, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $55.00 |
| Aug 12, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $55.00 |
| Aug 12, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $43.00 |
| Aug 12, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $55.00 |
| Jun 13, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| May 14, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $55.00 |
| May 13, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $47.00 |
| May 13, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $55.00 |
| May 13, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $55.00 |
| May 13, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $53.00 |
| May 13, 2025 | Needham | Serge Belanger | Buy | Maintains | $55.00 |
| May 7, 2025 | Chardan Capital | Rudy Li | Buy | Initiates | $55.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $52.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $53.00 |
Xenon Pharmaceuticals Inc. (XENE) Competitors
The following stocks are similar to Xenon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
XENE
Xenon Pharmaceuticals
mkt cap
3.48B
Xenon Pharmaceuticals Inc. (XENE) Financial Data
Xenon Pharmaceuticals Inc. has a market capitalization of $3.48B with a P/E ratio of -14.8x. The company generates $7.50M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,543.7% and return on equity of -45.1%.
Valuation Metrics
Market Cap
$3.48B
Enterprise Value
$3.02B
P/E Ratio
-14.8x
PEG Ratio
-0.4x
Price/Sales
463.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-4,543.7%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.4%
Current Ratio
12.5x
Debt/Equity
1.5x
ROE
-45.1%
ROA
-29.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xenon Pharmaceuticals Inc. (XENE) Business Model
About Xenon Pharmaceuticals Inc.
What They Do
Develops therapeutics for neurological disorders.
Business Model
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on researching and developing innovative treatment candidates for neurological conditions. The company generates revenue primarily through collaborations and partnerships with larger pharmaceutical firms, as well as potential future product sales once therapies receive regulatory approval.
Additional Information
The company is based in Canada and leverages proprietary technologies and expertise in ion channel genetics. By targeting niche therapeutic areas with significant unmet medical needs, Xenon Pharmaceuticals aims to improve treatment options for patients with epilepsy and rare neurological conditions, contributing to advancements in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
316
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Country
Canada
IPO Year
2014
Website
www.xenon-pharma.comXenon Pharmaceuticals Inc. (XENE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 04, 2025
By Zacks Equity Research
Realtime BLOG
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dec 03, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced new data on epilepsy treatments, including 48-month results from its azetukalner study and findings on depression and ASM titration, presented at AES 2025.
Why It Matters
Xenon Pharmaceuticals' new data on epilepsy treatments could enhance its market position, attract investment, and impact stock performance based on investor confidence in its drug pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters
Xenon Pharmaceuticals' recent earnings report may signal future performance, impacting investor sentiment and stock price movements based on financial health and growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
6 days ago
Quick Summary
Xenon Pharmaceuticals will host an investor webinar on Dec. 3, 2025, to present data from the AES 2025 meeting, including updates on azetukalner for focal onset seizures and its commercialization.
Why It Matters
Xenon Pharmaceuticals' webinar on new data for azetukalner and commercialization plans may signal potential growth and market interest, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xenon Pharmaceuticals granted 39,250 share options to five new employees as inducements for employment, approved by its Compensation Committee, effective December 4, 2025.
Why It Matters
Xenon Pharmaceuticals is incentivizing new hires with equity grants, indicating growth potential and attracting talent, which can positively impact future performance and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Polarean Imaging PLC (AIM:POLX) shares rose 12% to 0.14p after receiving Philips' approval for its XENOVIEW 3T chest coil, facilitating broader adoption of Xenon-based lung scans.
Why It Matters
Polarean Imaging's stock surge reflects investor confidence after achieving a key milestone for its lung scan technology, enhancing its market potential and partnership with Philips.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Polarean Imaging PLC has entered the Asian market with a deal to install a Xenon MRI system at National Taiwan University Hospital, facilitated by Philips and its new distributor Sumtage.
Why It Matters
Polarean Imaging's expansion into Asia with a deal in Taiwan enhances market reach, potentially boosting revenue and investor confidence in growth prospects.
Source: Proactive Investors
Market Sentiment:
Positive
Frequently Asked Questions About XENE Stock
What is Xenon Pharmaceuticals Inc.'s (XENE) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Xenon Pharmaceuticals Inc. (XENE) has a median price target of $55.00. The highest price target is $65.00 and the lowest is $44.00.
Is XENE stock a good investment in 2026?
According to current analyst ratings, XENE has 20 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XENE stock?
Wall Street analysts predict XENE stock could reach $55.00 in the next 12 months. This represents a 23.5% increase from the current price of $44.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xenon Pharmaceuticals Inc.'s business model?
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on researching and developing innovative treatment candidates for neurological conditions. The company generates revenue primarily through collaborations and partnerships with larger pharmaceutical firms, as well as potential future product sales once therapies receive regulatory approval.
What is the highest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The highest price target for XENE is $65.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 46.0% increase from the current price of $44.53.
What is the lowest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The lowest price target for XENE is $44.00 from Benjamin Burnett at Wells Fargo, which represents a -1.2% decrease from the current price of $44.53.
What is the overall XENE consensus from analysts for Xenon Pharmaceuticals Inc.?
The overall analyst consensus for XENE is bullish. Out of 22 Wall Street analysts, 20 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $55.00.
How accurate are XENE stock price projections?
Stock price projections, including those for Xenon Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 4:19 AM UTC